Teladoc Health (NYSE: TDOC) announced its 2020 Q3 earning results on October 28th, 2020. According to the announcement, its total revenue increased 109% (YoY, 3 months), and total US paid membership increased 47%. In addition, the total visits increased 206%. As a result, adjusted EBITDA increased 338% indicating superior performance of the Teladoc’s business. However, due to the acquisition costs of Livongo, which was announced in July 2020, Teladoc recorded operating loss and net loss in this quarter.
Although net cash provided by operating activities increased 423%, free cash flow decreased significantly due to the acquisition costs. In this quarter, Teladoc issued fixed rate notes totaling $ 1 billion.
As for the growth and valuation of the stock price, expected PSR based on the revenue in this quarter is 16.3, the subscription ratio based on the access fees revenue is 78.5%, the free cash flow margin is -19.3%, and the growth of revenue is 109.3%. Although the apparent profitability is declining due to the impact of M&A, the growth of revenue is still high, indicating continuous growth of Teladoc in the future.
Teladoc Health, Inc. (NYSE: TDOC) Stock Chart
Important Notice
- Watanabe & Brothers’ Investment is holding shares of Teladoc Health.
- This report is provided solely for informational purpose and not intended for the purpose of soliciting investment in, or as a recommendation to purchase or sell any specific products.
- Any opinions or statements expressed in this report are based on the author’s personal and subjective views, and are not the official views of the organization to which the author belongs. In addition, although we have done our best efforts in making accurate assessments on the original financial statements, we cannot guarantee any complete accuracy of this report. We do not guarantee either that any future forecasts referred to in this report will certainly be realized. Investment in listed stocks, ETFs, etc. should be carried out under the responsibility of each investor, and even if the investor who read this report suffers a loss due to investment activities, Watanabe & Brothers’ Investment is not responsible for any liability.
- This report was originally prepared in English, and translated into the other languages with plugin utilizing Google Translation API. We hereby notify that the translations are provided only for the sake of reference, and any opinions or statements in this report should be interpreted in original English. We ask any investors reading this report to refer to the original financial statements issued by the company.